Sagimet Biosciences (SGMT) said Tuesday the US Food and Drug Administration's Division of Dermatology and Dentistry has cleared its investigational new drug application for TVB-3567.
The company said the clearance allows it to enter clinical development for the treatment of acne, with a first-in-human phase 1 trial planned in 2025.
TVB-3567 is its second fatty acid synthase inhibitor, it said.
Price: 3.37, Change: -0.17, Percent Change: -4.80
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。